Influenza Vaccine Market : Global Demand Analysis & Opportunity Outlook 2021

Global Influenza vaccine Market Overview

The Global Influenza Vaccine Market has marked a moderate growth in recent years due to various factors like awareness among the nations, development in rural regions and advancement of technology in the field of medical facilities.

Global Influenza Vaccine market boosts up as the new researches came into existence which enhances the vaccinations as well as the availability of vaccines at lower cost which in results offers convenience for the consumers across the globe.

Governmental authorities worldwide are approaching towards the awareness of vaccinations to the population which further fuelled up the global market of influenza vaccines.

The Global Influenza Vaccine Market is expected to reach the revenue of USD 45.25 Billion by 2021 from USD 30.45 Billion in 2015, expanding at a CAGR of 7.9%. The Global Market of Influenza Vaccine is anticipated to grow in upcoming years as the chances of occurring of influenza is equal in both developed & developing nations.

US was the largest influenza vaccine market in the year 2010 followed by China. Due to presence of bacteria in the environment rises the number of infected persons in the respective nations in 2010.

The rapid growth in population and acquisition of land for the infrastructural facilities would raise the congestion level across the globe which would further leads to have more casualties of influenza and this increasing numbers of casualties would fuelled up the growth of Influenza vaccine across the globe.

Market Segmentation

By Product

On the basis of product, we have studied the market on the following vaccines:-

• Conjugate vaccines
• Live Attenuated vaccines
• Inactivated and Subunit Vaccines
• Toxoid vaccines
• Recombinant vaccines

By Type

Depending upon the type of vaccine, an in-depth analysis has been done on below mentioned vaccines:-

• Monovalent vaccines
• Multivalent vaccines

By End-user

Based on end user, the Global Influenza Vaccine market is segmented as:

• Pediatrics
• Adults

By Region

Global Influenza Vaccine Market is further classified on the basis of region as follows:

• North America (U.S. & Canada)
• Latin America (Brazil, Mexico, Rest of Latin America)
• Western and Eastern Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, Rest of Western Europe)
• Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of Asia)
• Rest of World

Growth Drivers and challenges

Continuous growth in population and population density worldwide increases of infectious disease spread followed by seasonal outbreaks. In addition to that, rising awareness among the people and initiatives taken by the local bodies government to drive the global market of influenza vaccine in near future.

Further, rising medical healthcare services and governmental initiative like vaccination programs are projected to give a boost tot the demand of the influenza vaccine market globally.

However, limited expenditure on healthcare services in developing and under-developed countries forces the demand of infuelza vaccine to remain range bound towards lower side. The virus circulating in the environment where the population density is more and availability of vaccines is limited would be a huge restraint for global influenza vaccine market.

Key Players

• Astellas Pharma Inc.
• CSL Limited
• Emergent Bio Solution Inc.
• GlaxoSmithKline
• Johnson & Johnson
• Revlon
• Serum Instt. Of India Pvt Ltd.
• Sinovac Biotech
• Sanofi

Segmentation

• By Product
• By Type
• By End-user

Market Dynamics

Supply & Demand Risk

Competitive Landscape

Porter’s Five Force Model

Geographical Economic Activity

Key Players (respective SWOT Analysis) and their Strategies and Product Portfolio

Recent Trends and Developments

Industry Growth Drivers and Challenges

Key Information for Players to establish themselves in current dynamic environment

Recent News & Developments

February 26 2016: Scientists from Newcastle University revealed a discovery of human skin cells which helps to produce more effective anti-aging products and cancer treatment by the action of metabolic enzyme drops as one ages.

August 16 2016: The Food and Drug Administration approved the over-the-counter sale of Differin, which had only been available by prescription. It is a retinol product that helps with anti-aging.

August 16 2016: Biostem Technologies Inc. & Niche Pharmaceuticals are working in the advancement of anti-aging products strategies and manufacturing by providing financial marketing and capital advisory to small-cap organizations.

                Key Answers Captured in Report?